Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Zhu X, Koshkin VS. Med 2024;5:106-108.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhu X, Koshkin VS. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Med 2024;5:106-108.
PMID: 38128535